['hiv-1 infection']
['dolutegravir, 50mg every 24 hours', 'protease inhibitor/ritonavir']

        Inclusion Criteria:

          1. HIV-infected patients over 18 years.

          2. In current antiretroviral therapy with abacavir and lamivudine (Kivexa) plus
             ritonavir-boosted PI, at least 6 months.

          3. Viral suppression (HIV RNA <50 copies / ml) for at least 12 months.

          4. T-score ≤ -1 evaluated by DEXA (done in the last 6 months).

          5. Signed informed consent.

          6. In potential childbearing women, commitment to use barrier contraceptive method
             throughout the study.

        Exclusion Criteria:

          1. Suspected or documented resistance to integrase inhibitors or reverse transcriptase
             inhibitors, nucleoside analogues.

          2. Osteoporosis / osteopenia secondary (testosterone deficiency, thyroid disease ...),
             except vitamin D deficiency

          3. Treatment with bisphosphonates in the last 6 months.

          4. Have used integrase inhibitors

          5. Pregnant or breastfeeding.

          6. Patients with alanine aminotransferase (ALT)> 5 times the upper limit of normal (ULN)
             or ALT ≥ 3 times ULN and bilirubin ≥ 1.5 times ULN (direct bilirubin> 35%)

          7. Patients with severe hepatic dysfunction (Class B or C) according to the Child-Pugh
             classification

          8. Patients infected with hepatitis B virus (HBV) who can not use entecavir or
             telbivudine.

          9. Patients infected with hepatitis C virus (HCV) in which is expected to begin treatment
             during the study.
      